NCT06473532 TEXT4HF: A Randomized Controlled Trial of a Tailored Text Messaging Intervention to Improve Self-Care in Older Adult Patients With Heart Failure
| NCT ID | NCT06473532 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Chicago |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-09-26 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-09-26 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to determine whether an individually tailored text messaging intervention can improve self-care in older adult patients with heart failure. The main question it aims to answer are: * Is a tailored text messaging intervention feasible and acceptable among older adult patients with heart failure? * Does tailored text messaging improve self-care in adult patients with heart failure? Participants will be randomly assigned to one of two groups for 12 weeks: 1) intervention (text messaging); or 2) control group. Both groups will receive usual care, which includes regular follow-up visits at the heart failure clinic (standard care), plus a "Discharge Packet for Patients Diagnosed with Heart Failure", developed by the American Heart Association. Both groups will be asked via text messages and/or telephone calls to complete questionnaires at baseline/start, 4 weeks and 12 weeks, about self-care, quality of life, health beliefs, medications, diet, etc. Participants assigned to the intervention group will also receive approximately 5 text messages/week targeting medication adherence, heart-healthy diet, and self-monitoring for 12 weeks.
Eligibility Criteria
Inclusion Criteria: * ≥50 years of Age * HF Stage C, NYHA Class I-IV and on a loop diuretic * Own a Mobile phone with Text message plan * Ability to speak and read English * Suboptimal HF self-care. (SCHFI Score of 3 or less in at least 2 items of any subscale: Self-care maintenance, Symptom Perception, or Self-management) Exclusion Criteria: * SAVR/TAVR or Ventricular Assist Device, or Cardiac Resynchronization Therapy (CRT) - implantation, and/or heart transplantation (HTx) scheduled within the next 3 months * Coronary revascularization, and/or CRT-implantation within the last 30 days (EMR Review) * Psychosis * Hospice or End-of-life care * Advanced Renal disease (i.e., estimated Glomerular Filtration Rate \<25 or Hemodialysis) * Cognitive impairment (i.e., Dementia, Alzheimer's) * Unable to self-manage (take medication, bathe, use the toilet, etc.) * Currently living in a nursing home
Contact & Investigator
Jonathan W Leigh, MPH, MSHI
PRINCIPAL INVESTIGATOR
University of Illinois at Chicago
Frequently Asked Questions
Who can join the NCT06473532 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06473532 currently recruiting?
Yes, NCT06473532 is actively recruiting participants. Contact the research team at leighj@uic.edu for enrollment information.
Where is the NCT06473532 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06473532 clinical trial?
NCT06473532 is sponsored by University of Illinois at Chicago. The principal investigator is Jonathan W Leigh, MPH, MSHI at University of Illinois at Chicago. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.